INTRODUNCTION
Prostate cancer (PCa) is the most common cancer among males and the
second most common cancer worldwide. In addition, it ranks fifth among
the causes of cancer-related mortality (1). In daily practice, unlike
many types of cancer, PCa is divided into clinically significant (csPCa)
and clinically insignificant tumors (cisPCa), and this differentiation
is directly related to the survival of the patient (2). Although the
widespread use of serum prostate specific antigen (PSA) screening has
led to a decrease in cancer-related deaths, it also results in a greater
rate of cisPCa diagnosis and treatment (3). The priority in the
management of patients diagnosed with PCa is to accurately evaluate the
presence of csPCa, effectively demonstrate the extent of the disease at
the time of diagnosis, and predict the risk of progression (3). For this
purpose, multiparametric magnetic resonance imaging (mpMRI) has been
increasingly used in recent years, extending the area of use of targeted
biopsies and increasing accuracy rates in the differentiation of csPCa
and staging (4).
The Prostate Imaging Reporting and Data System (PI-RADS) scoring, which
is used to classify and standardize findings defined in the prostate,
facilitates the clinical use of mpMRI (5). In addition to the diagnosis
of PCa, mpMRI provides information for the correct assessment of the
risk of extraprostatic spread (EPE), seminal vesicle invasion (SVI), and
lymph node metastasis (LNM) and may affect the treatment strategy (6).
Since the PI-RADS scoring used during the evaluation of mpMRI includes
some subjective criteria, the sensitivity of the examination varies
depending on the experience of the evaluating physician (5). This
increases the importance of using parameters that can be standardized,
such as prostate lesion size in order to increase the capacity of mpMRI
in determining morphological and functional results, and the lesion size
is considered to be correlated with clinical parameters (7).
In this study, we aimed to investigate the relationship between lesion
size determined using mpMRI and histopathological findings of specimens
obtained after mpMRI/transrectal ultrasound (TRUS) fusion biopsy and
radical prostatectomy (RP).